Insider Selling: Exelixis, Inc. (NASDAQ:EXEL) Director Sells 12,210 Shares of Stock

Exelixis, Inc. (NASDAQ:EXEL) Director Mary C. Beckerle sold 12,210 shares of the company’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $34.88, for a total transaction of $425,884.80. Following the sale, the director now directly owns 30,406 shares in the company, valued at $1,060,561.28. This trade represents a 28.65 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Exelixis Trading Up 2.5 %

Shares of NASDAQ:EXEL traded up $0.87 on Wednesday, reaching $35.07. 2,825,388 shares of the company traded hands, compared to its average volume of 2,626,587. Exelixis, Inc. has a 52 week low of $20.14 and a 52 week high of $37.59. The business’s 50-day simple moving average is $34.16 and its 200 day simple moving average is $31.11. The stock has a market capitalization of $9.82 billion, a P/E ratio of 19.81, a price-to-earnings-growth ratio of 1.13 and a beta of 0.53.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. Sell-side analysts expect that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price target on shares of Exelixis in a report on Thursday, February 13th. Piper Sandler boosted their target price on Exelixis from $37.00 to $38.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 12th. BMO Capital Markets cut Exelixis from an “outperform” rating to a “market perform” rating and raised their price target for the company from $36.00 to $40.00 in a report on Friday, December 20th. Morgan Stanley raised Exelixis from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $30.00 to $40.00 in a report on Monday, January 27th. Finally, Truist Financial raised their target price on shares of Exelixis from $42.00 to $43.00 and gave the company a “buy” rating in a research note on Monday, January 27th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $37.24.

Hedge Funds Weigh In On Exelixis

Several hedge funds and other institutional investors have recently modified their holdings of EXEL. Coppell Advisory Solutions LLC purchased a new position in Exelixis during the 4th quarter valued at about $25,000. Colonial Trust Co SC increased its stake in shares of Exelixis by 616.9% during the fourth quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 765 shares during the period. Principal Securities Inc. raised its holdings in shares of Exelixis by 62.8% during the fourth quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 373 shares in the last quarter. USA Financial Formulas purchased a new stake in Exelixis in the fourth quarter worth $32,000. Finally, V Square Quantitative Management LLC bought a new stake in Exelixis in the third quarter valued at $30,000. 85.27% of the stock is owned by institutional investors.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.